This Canadian Pharmaceutical Company Has Developed an ‘Off-Switch’ For LSD Trips

Article by Angela Stelmakowich, Growth Op

Canadian psychedelic pharmaceutical company, Mind Medicine Inc., claims it has identified what no amount of “there, there-ing” from even the closest friend could achieve: flipping the off-switch on a bad acid trip.

MindMed suggests the solution would be a much-needed fix for therapists who administer psychedelics to patients. It may also help bolster the therapeutic potential of LSD and shorter-acting psychedelic therapy treatments, according to the company.

Working with the Liechti Laboratory in Switzerland, MindMed reported last week that it had developed what the company soothingly calls “LSD neutralizer technology to shorten and stop LSD trips.”

Thinking ahead about the technology’s potential — given the explosion of interest in psychedelics at the moment — MindMed filed a patent application in the U.S., which would preserve all worldwide rights.

The idea is to “help reduce the acute effects of a psychedelic drug and help shorten the hallucinogenic effects when required by a patient or medical professional,” notes the company. “This discovery, when further developed, may act as the ‘off-switch’ to an LSD trip.”

Switzerland is both the birthplace of LSD and home to some of the world’s oldest LSD-assisted psychotherapy clinics, according to Merry Jane.

MindMed, for its part, became one of the first psychedelics companies to list on the NEO Exchange, Canada’s next-generation stock exchange. Former Canopy Growth CEO Bruce Linton serves on the company’s Board of Directors. Linton is also an investor, as is Kevin O’Leary of Dragon’s Den and Shark Tank fame.

Read the full article here.